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Abstract
Patient-related risk factors for invasive Staphylococcus aureus
infection overlap with those for periprosthetic joint infections
(PJIs). We compared these factors and clinical characteristics
between 17 exogenous and 40 haematogenous PJIs caused by
S. aureus. Exogenous cases presented signiﬁcantly more often
with damaged periprosthetic soft tissue, whereas haematogenous
cases more often had systemic signs of infection, such as fever,
chills, and sepsis syndrome. However, comorbid conditions asso-
ciated with S. aureus infection and/or PJIs did not differ between
the two groups. These ﬁndings imply that patient-related risk
factors for S. aureus infection do not help to predict the mode
of infection acquisition in prosthetic joints.
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Staphylococcus aureus is one of the most common pathogens
of periprosthetic joint infections (PJIs). The mode of infection
is either exogenous (mainly perioperatively acquired) or hae-
matogenous from a distant source [1]. Interestingly, patient-
related risk factors for invasive S. aureus infection partially
overlap with those for PJIs [2,3]. Patients with multiple risk
factors are prone to develop postoperative complications
[4]. However, these factors and clinical characteristics for
exogenous and haematogenous PJIs caused by S. aureus have
not been compared. Therefore, we retrospectively evaluated
demographic variables, comorbidities, clinical and laboratory
values at admission and 30-day mortality rates between
exogenous and haematogenous infections within our cohort
of hip and knee PJIs.
Patient charts of PJI cases caused by S. aureus were
reviewed in detail. Diagnosis included S. aureus in ‡2 speci-
mens (tissue biopsy or synovial ﬂuid) or, in cases of S. aureus
sepsis-related death, acute inﬂammation in histopathology
specimens at necropsy. Exogenous PJI included diagnosis
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£3 months after implantation and no remote source of infec-
tion. Haematogenous PJI diagnosis included a distant primary
focus or diagnosis made ‡2 years after implantation. PJIs
caused by small-colony variants of S. aureus were excluded,
because infection manifestation may occur many years after
inoculation [5], and differentiating exogenous and haemato-
genous infection is therefore difﬁcult. A t-test, Fisher’s exact
test or Pearson chi-square test was applied where appropri-
ate. A two-tailed p-value of <0.05 was considered to be
signiﬁcant.
From 1998 to 2008, 73 hip and knee PJIs caused by S. aur-
eus were identiﬁed in our cohort. Sixteen episodes were
excluded: two had insufﬁcient data, eight occurred between
3 and 24 months and had no obvious primary focus, and ﬁve
were caused by small-colony variants of S. aureus [6]. In addi-
tion, one exogenous case was excluded because infection
was traumatically acquired 3.5 years after implantation.
Hence, 57 staphylococcal PJIs, including 17 (30%) exogenous
and 40 (70%) haematogenous cases, were analysed.
The median time intervals from implantation to infection
were 1 month (interquartile range 0.5–2) in the exogenous
cases and 86 months (interquartile range 39–128) in the hae-
matogenous cases. In the latter group, four infections
occurred at <24 months, but an obvious primary focus was
identiﬁed. In the haematogenous cases, a source of infection
was identiﬁed in 17 (43%) cases (Table 1). Clinical character-
istics of both groups are presented in Table 2. In the hae-
matogenous group, there were more patients with hip
prosthesis (73% vs. 47%, p 0.06), and in the exogenous group
there were more patients with knee prostheses (53% vs.
27%, p 0.06). This difference was also observed when total
hip arthroplasties were compared with total knee arthropla-
sties. Infected hip prostheses more frequently had a haemat-
ogenous origin (78% vs. 55%, p 0.06), and knee prostheses
an exogenous origin (45% vs. 22%, p 0.06). However, age,
sex and comorbidities did not differ signiﬁcantly between the
two groups (Table 2). Clinical and laboratory ﬁndings at
admission are also presented in Table 2. All exogenous PJI
cases presented with damage to the periprosthetic soft tis-
sue; in haematogenous PJIs, these ﬁndings were reported in
only 12 of 40 cases (100% vs. 30%, p <0.0001). Haemato-
genous cases presented signiﬁcantly more often with sys-
temic signs of infection, such as fever, chills, and sepsis
syndrome. Similarly, these cases had signiﬁcantly higher
values for C-reactive protein and band forms of neutrophil
granulocytes (Table 3). The 30-day mortality rates were 0%
in the exogenous group and 18% (seven of 40 cases, of
which ﬁve were attributed to S. aureus sepsis) in the haemato-
genous group (p 0.09). Mortality was associated with sepsis
syndrome at admission (p <0.0001) and positive blood
culture for S. aureus (p 0.0008).
We hypothesized that, in patients with exogenous PJIs,
certain comorbidities would be more prevalent and that the
total number of these variables for both S. aureus and PJIs
TABLE 1. Sources of infection in 40 haematogenous peri-
prosthetic joint infections caused by Staphylococcus aureus
Infection source No. (%)
No source identiﬁed 23 (57.5)
Previous bacteraemia without identiﬁed source 5 (12.5)
Joint and bone 5 (12.5)
Skin and soft tissue 4 (10)
Respiratory tract 3 (7.5)
TABLE 2. Demographic data and comorbid conditions in 57
episodes of periprosthetic joint infections (PJIs) caused by
Staphylococcus aureus
Characteristics
Exogenous
PJI (n = 17)
Haematogenous
PJI (n = 40) p-Value
Median age (years) (IQR) 72 (67–74) 69 (60–78) 0.89
Male 8 (47) 22 (55) 0.58
Infected hip prosthesis 8 (47) 29 (73) 0.06
Infected knee prosthesis 9 (53) 11 (27) 0.06
Median no. of comorbidities (IQR) 1 (1–2) 1 (1–2) 0.98
Two or more comorbidities 7 (41) 19 (48) 0.66
No comorbidities 1 (6) 7 (18) 0.41
Diabetes 2 (12) 9 (23) 0.47
Rheumatic disease 1 (6) 4 (10) 1.00
Chronic heart failure 6 (35) 14 (35) 1.00
Chronic lung diseases 1 (6) 5 (13) 0.65
Chronic skin diseases 1 (6) 0 (0) 0.29
Liver diseases 1 (6) 2 (5) 1.00
Renal diseases 1 (6) 6 (15) 0.35
Cancer 0 (0) 0 (0) –
IVDU 0 (0) 1 (3) 1.00
Obesity 7 (41) 7 (25) 0.09
IQR, interquartile range; IVDU, intravenous drug use.
Data are shown as no. (%) unless otherwise indicated.
TABLE 3. Clinical and laboratory ﬁndings at admission in 57
episodes of periprosthetic joint infections (PJIs) caused by
Staphylococcus aureus
Characteristics
Exogenous
PJI (n = 17)
Haematogenous
PJI (n = 40) p-Value
Clinical ﬁndings
Soft tissue damagea 17 (100) 12 (30) <0.0001
Pain 8 (47) 29 (73) 0.06
Feverb 4 (24) 23 (58) 0.01
Chills 2 (12) 19 (48) 0.01
Sepsis syndromec 1 (6) 14 (35) 0.04
Laboratory ﬁndings
Median leukocytes (g/L) (IQR) 10.4 (6.6–12.8) 11.7 (9.2–16.4) 0.13
Neutrophil granulocytes
Band forms, % (IQR) 3 (2–11) 21 (12–27) 0.02
Median C-reactive protein
(mg/L) (IQR)
46 (17–110) 164 (73–261) 0.01
S. aureus in blood cultures 2 (12) 13 (33) 0.18
IQR, interquartile range.
Data are shown as no. (%) unless otherwise indicated.
aWound, sinus tract and abscess were considered to be soft tissue damage.
bBody temperature ‡38.3C was considered to be fever.
cSepsis criteria were applied according to published recommendations [9].
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would be higher than in patients with haematogenous PJIs.
Patient-related risk factors for PJI include obesity, rheuma-
toid arthritis, cancer, immunosuppression, and diabetes mell-
itus [2,4]. The most common predisposing conditions in
invasive S. aureus infections are dialysis use, rheumatoid
arthritis, diabetes mellitus, and cancer [3]. However, within
our study population, these factors did not differ between
exogenous and haematogenous infections.
Notably, only 30% of the episodes were exogenous PJIs.
This ﬁnding contrasts with those of other studies, in which
most PJIs, irrespective of the pathogen, were diagnosed
within the ﬁrst year (i.e. mainly exogenous infections) [4].
We used the time interval from implantation to infection
and the presence of a distant infectious source to distinguish
between exogenous and haematogenous infection. S. aureus
mainly causes very early exogenous or, more commonly, late
haematogenous infections. Additional factors inﬂuencing the
disparity between exogenous and haematogenous infections
may be centre-speciﬁc. Institutions that do not follow their
cases as a cohort observe a higher proportion of early exog-
enous infections. In our centre, strict hygiene precautions
are applied to all patients irrespective of risk proﬁle, both
preoperatively and postoperatively, within the orthopaedic
infection unit. Also, patients are not discharged unless the
wound is completely dry. Hence, because the overall propor-
tion of exogenous infections after arthroplasty is very low in
our centre (<0.5%) [7], we observe predominantly haemat-
ogenous infections.
Exogenous infections were more frequent after knee
arthroplasty, and haematogenous infections were more fre-
quent after hip arthroplasty. It is conceivable that the critical
soft tissue condition surrounding knee prostheses increases
the risk of exogenous infection. Similarly, the number of
exogenous PJIs in hip arthroplasties might be underestimated,
because we excluded all cases occurring between 3 and
24 months after implantation. Yet, six of these eight cases
presumably had a haematogenous origin; including them
would not have inﬂuenced the proportions of knee and hip
prostheses.
As expected, exogenous infections presented more often
with local signs, and haematogenous infections with systemic
signs. Considering the strict inclusion criteria and the
detailed review of patient charts, we can exclude a haemat-
ogenous origin in the exogenous PJI group. The 30-day mor-
tality rate was higher in the haematogenous cases. However,
this observation was associated with the presence of sepsis
syndrome and bacteraemia rather than with patient-related
variables associated with S. aureus infection or PJI [8].
Our data suggest that, in patients with PJIs caused by
S. aureus, demographics and comorbidities are similar in
exogenous and haematogenous cases, provided that strict
hygiene precautions are applied during implantation. This
implies that patient-related risk factors for invasive S. aureus
infection do not help to identify patients at risk for exoge-
nous staphylococcal PJIs. Also, patients with prosthetic joints
have a life-long risk of acquiring haematogenous PJIs.
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